Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy.

Patients with more than 3 risk factors did not seem to benefit from CN. Importantly, OS in this group was equivalent to, if not higher than, OS for patients in the CN plus sunitinib arm of CARMENA, and this raises the possibility that a well-selected population might benefit from CN.